Screener
Sutro Biopharma STRO Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Sutro Biopharma in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The source filing: Sutro Biopharma’s 10-Q, filed May 14, 2026.
- Filed
- May 14, 2026, 4:30 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-224170
| Line item | Three Months Ended / March 31, 2026 | Three Months Ended / March 31, 2025 |
|---|---|---|
| Accrued expenses and other liabilities | 8,403 | 5,553 |
| Deferred revenue | (1,958) | (4,775) |
| Operating lease liability | (2,042) | (1,757) |
| Net cash used in operating activities | (42,259) | (67,883) |
| Investing activities | ||
| Purchases of marketable securities | (124,703) | (142,380) |
| Maturities of marketable securities | 76,210 | 105,800 |
| Sales of marketable securities | 3,240 | 21,496 |
Item 1. Financial Statements.
FAQ
- What is Sutro Biopharma's operating cash flow?
- Sutro Biopharma (STRO) reported operating cash flow of -$42.26M in Q1 2026.
- How has Sutro Biopharma's operating cash flow changed year-over-year?
- Sutro Biopharma's operating cash flow increased by 37.7% year-over-year, from -$67.88M to -$42.26M.
- What is the long-term trend for Sutro Biopharma's operating cash flow?
- Over 2 years (2021 to 2025), Sutro Biopharma's operating cash flow has grown at a 47.3% compound annual growth rate (CAGR), from -$81.68M to -$177.23M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.
Ask your AI about Sutro Biopharma's operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude